Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Licenses Quantovir's HPV IP to Develop Predictive Dx for Cervical Cancer

NEW YORK (GenomeWeb News) - Cepheid said today that it plans to use a family of human papillomavirus patents it has exclusively licensed from the Swedish company Quantovir to develop a PCR-based diagnostic test for HPV that will predict a woman’s risk for developing cervical cancer.
Ceppheid said the test, which will run on the GeneXpert system, will harness Quantovir's technology to create an HPV diagnostic that will measure HPV viral load. This capability, the company said, “may help to identify patients most at risk” of developing cervical cancer and will also make the test “unique among current HPV DNA testing products.”
Cepheid CEO John Bishop said in a statement that the company expects the HPV test to "provide accurate PCR results in minutes rather than days in a variety of clinical settings."
The estimated market for HPV diagnostic preventative testing may be between $600 million and $700 million, the company said.
Quantovir was founded in 2001, when it was spun out from the Genetics and Pathology department at Uppsala University.
Financial terms of the agreement were not released.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.